Israel reopens anti-dumping probe on Canadian medical cannabis imports

Fresh investigation signals potential trade friction as Canadian producers report domestic growth.

FILE — statehouse · B.D. Gilfry / CC BY-SA 2.0

Israel has reopened an anti-dumping investigation into Canadian medical cannabis, according to StratCann. The move introduces a fresh trade-policy variable for Canadian exporters at a moment when domestic operators report expansion: High Tide posted record Q3 2026 growth across Canadian and German operations, while Canadian cannabis employment grew in August 2026.

Anti-dumping probes typically examine whether imports are priced below fair value, potentially damaging local producers. The timing suggests Israel may view Canadian medical cannabis as a competitive pressure point in its domestic market. The investigation's scope and timeline remain unclear from available reporting.

Watch whether the probe results in tariffs or import restrictions, and whether Canadian industry groups—notably the Cannabis Council of Canada, which suspended active operations in June—coordinate a response. Broader export dynamics will merit attention as well.